IP Verse

Psma Binding Ligand-Linker Conjugates And Methods For Using - EP2187965

The patent EP2187965 was granted to Purdue Research Foundation on Oct 9, 2019. The application was originally filed on Aug 15, 2008 under application number EP08798020A. The patent is currently recorded with a legal status of "Revoked".

EP2187965

PURDUE RESEARCH FOUNDATION
Application Number
EP08798020A
Filing Date
Aug 15, 2008
Status
Revoked
Mar 3, 2021
Grant Date
Oct 9, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTJul 7, 2020BOULT WADE TENNANT -
ORANO MEDJul 7, 2020BREVALEX -

Patent Citations (27) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007160617
DESCRIPTIONUS5795877
DESCRIPTIONUS5863536
DESCRIPTIONUS5902817
DESCRIPTIONUS5962521
DESCRIPTIONUS5968915
INTERNATIONAL-SEARCH-REPORTUS2004029778
INTERNATIONAL-SEARCH-REPORTUS2007160617
INTERNATIONAL-SEARCH-REPORTUS6368598
INTERNATIONAL-SEARCH-REPORTUS6479470
INTERNATIONAL-SEARCH-REPORTUS7128893
OPPOSITIONEP1999136
OPPOSITIONEP2170075
OPPOSITIONUS2003138432
OPPOSITIONUS7128893
OPPOSITIONWO02098885
OPPOSITIONWO0243773
OPPOSITIONWO03000201
OPPOSITIONWO03060523
OPPOSITIONWO03092742
OPPOSITIONWO2006012527
OPPOSITIONWO2006093991
OPPOSITIONWO2007022493
OPPOSITIONWO2007106869
OPPOSITIONWO2008057437
OPPOSITIONWO2008058192
OPPOSITIONWO2009002529

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Ouabain", Wikipedia, (20200604), pages 1 - 6, URL: https://en.wikipedia.orq/w/index.php?title=Ouabain&oldid=956105385, XP055766112
OPPOSITION- Crystal Dusich; Ron Mease; Catherine Foss; Martin Pomper, "General Approach for the Préparation of Fluorescent PSMA/GCPII Inhibitors", Molecular Imaging, (20060000), vol. 5, no. 3, pages 322 - 323, XP055762959
OPPOSITION- JAYAPRAKASH et al., "Design and Synthesis of a PSMA Inhibitor-Doxorubicin Conjugate for Targeted Prostate Cancer Therapy", ChemMedChem., (20060300), vol. 1, no. 3, pages 299 - 302, XP002390389
OPPOSITION- Jeroen R Mesters, Cyril Barinka, Weixing Li, Takashi Tsukamoto, Pavel Majer, Barbara S Slusher, Jan Konvalinka, And Rolf Hilgenfeld, "Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer", MBOJ., (20060322), vol. 25, no. 6, pages 1375 - 1384, XP055766101
OPPOSITION- Joseph A. Reddy, Le-Cun Xu, Nikki Parker, Marilynn Vetzel And Christopher P. Leamon, "Preclinical Evaluation of 99mTc-EC20 for Imaging Folate Receptor-Positive Tumors", J Nucl Med., (20040500), vol. 45, no. 5, pages 857 - 866, XP055766108
OPPOSITION- LEUNG K, "111ln-Capromab pendetide", Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD), (20050000), pages 1 - 6, XP055766117
OPPOSITION- MEASE et al., "Molecular Imaging", The Fifth Annual Meeting of the Society for Molecular Imaging, (20060000), pages 1 - 209, XP055766047
OPPOSITION- S. JAYAPRAKASH et al., "Design and Synthesis of a PSMA Inhibitor-Doxorubicin Conjugate for Targeted Prostate Cancer Therapy", ChemMedChem, (20060000), vol. 1, no. 3, pages 299 - 302, XP002390389
OPPOSITION- J. C. DOS SANTOS et al., "Development and dosimetry of 203Pb/12Pb-labeled PSMA ligands: bringing ''the lead'' into PSMA-targeted alpha therapy?", European Journal of Nuclear Medicine and Molecular Imaging 2019, (20190103), vol. 46, no. 5, doi:10.1007/s00259-018-4220-z, pages 1081 - 1091, XP036752449
OPPOSITION- ZACHARIAS et al., "Cation-@p interactions in ligand recognition and catalysis", Trends Pharmacol Sci., (20020600), vol. 23, no. 6, pages 281 - 287, XP004367078
OPPOSITION- M. BENES?OVÁ et al., "Linker Modification Stratégies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors", Journal of Médicinal Chemistry, (20160000), vol. 59, no. 5, doi:10.1021/acs.jmedchem.5b01210, pages 1761 - 1775, XP055289267
OPPOSITION- M. EDER et al., "68Ga-Complex Lipophilicity and the Targeting Property of a Urea-based PSMA Inhibitor for PET Imaging", Bioconjugate Chemistry, (20120000), vol. 23, no. 4, doi:10.1021/bc200279b, pages 688 - 697, XP055043532
OPPOSITION- A. P. KOZIKOWSKI et al., "Design of Remarkably Simple, Yet Potent Urea Based Inhibitors of Glutamate Carboxypeptidase (NAALADase", J. Med. Chem., (20010000), vol. 44, doi:10.1021/jm000406m, pages 298 - 301, XP002196918
OPPOSITION- A. P. KOZIKOWSKI et al., "Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgésie Agents", J. Med. Chem., (20040000), vol. 47, doi:10.1021/jm0306226, pages 1729 - 1738, XP002390387
OPPOSITION- KOZIKOWSKI et al., "Synthesis of Urea-Based Inhibitors as Active Site Probes of Glutamate Carboxypeptidase II: Efficacy as Analgesic Agents", J Med Chem., (20040325), vol. 47, no. 7, pages 1729 - 1738, XP002390387
OPPOSITION- Sumith A Kularatne; Kevin Wang; Hari-Krishna R Santhapuram; Philip S Low, "Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand", Molecular Pharmaceutics, (20090500), vol. 6, no. 3, pages 780 - 789, XP055383058
OPPOSITION- Sumith A Kularatne; Zhigang Zhou; Jun Yang; Carol B Post; Philip S Low, "Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99m Tc-Radioimaging Agents", Mol Pharm., (20090500), vol. 6, no. 3, pages 790 - 800, XP055400629
OPPOSITION- ZHOU JIA; ET AL, "NAAG peptidase inhibitors and their potential for diagnosis and therapy", Nat Rev Drug Discov., (20051200), vol. 4, no. 12, pages 1015 - 1026, XP002514725
SEARCH- VLAHOV ET AL., "DESIGN AND REGIOSELECTIVE SYNTHESIS OF A NEW GENERATION OF TARGETED CHEMOTHERAPEUTICS", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2006), vol. 16, pages 5093 - 5096, XP002730835 [X] 1-15 * the whole document *
SEARCH- HENNE ET AL., "SYNTHESIS AND ACTIVITY OF A FOLATE PEPTIDE CAMPTOTHECIN PRODRUG", BIOORGANIC AND MECICINAL CHEMISTRY LETTERS, (2006), vol. 16, pages 5350 - 5355, XP002730834 [X] 1-16 * the whole document *
SEARCH- PARANJPE ET AL., "TUMOR-TARGETED BIOCONJUGATE BASED DELIVERY OF CAMPTOTHECIN", JOURNAL OF CONTROLLED RELEASE, (2004), vol. 100, pages 275 - 292, XP002730836 [X] 1-15 * the whole document *
SEARCH- YANG ET AL., "CHARACTERIZATION OF THE PH OF FOLATE RECEPTOR-CONTAINING ENDOSOMES AND THE RATE OF HYDROLYSIS OF INTERNALIZED ACID-LABILE FOLATE-DRUG CONJUGATES", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20070501), vol. 321, no. 2, pages 462 - 468, XP002730837 [X] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents